Moderna-Merck mRNA cancer vaccine success drives MRVI sympathy surge

 

• Moderna/Merck Phase 3 melanoma vaccine hit primary endpoints, sending MRNA +95% and related names higher
• MRVI provides critical mRNA reagents (e.g. CleanCap via TriLink) as a 'picks-and-shovels' play for mRNA ecosystem
• No Maravai-specific news; move is sector read-through with premarket volume confirming interest
• Stock up ~23% in premarket to ~$7.00 from $5.74 Aug 18 close per market data
• Follows Q2 2026 earnings (Aug 6) showing 9% revenue growth and improved Adj. EBITDA outlook
• Short interest ~3.4% of float adds potential fuel but not primary driver

https://finviz.com/stock?t=MRVI&p=d